Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| CELG | Celgene Corporation | 0.88% | 93.92 | 1.3% | $988.55m | |
| BIIB | Biogen Inc. | 2.45% | 229.89 | 1.3% | $619.18m | |
| AMGN | Amgen Inc. | 1.22% | 180.48 | 1.3% | $474.61m | |
| GILD | Gilead Sciences, Inc. | 2.13% | 64.14 | 0.9% | $448.87m | |
| ILMN | Illumina, Inc. | 1.49% | 319.20 | 3.5% | $295.43m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 2.80% | 349.99 | 2.6% | $291.08m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 1.18% | 174.61 | 1.9% | $236.35m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 4.30% | 135.68 | 2.0% | $176.60m | |
| EXAS | Exact Sciences Corporation | 0.27% | 95.39 | 25.3% | $169.11m | |
| A | Agilent Technologies, Inc. | 1.23% | 76.72 | 1.6% | $147.38m | |
| SRPT | Sarepta Therapeutics, Inc. | 1.74% | 120.22 | 14.7% | $129.47m | |
| ONCE | Spark Therapeutics, Inc. | 0.64% | 111.38 | 11.2% | $116.56m | |
| INCY | Incyte Corporation | 0.57% | 73.94 | 2.5% | $97.68m | |
| IONS | Ionis Pharmaceuticals, Inc. | 0.72% | 73.86 | 8.3% | $96.82m | |
| BMRN | BioMarin Pharmaceutical Inc. | -0.21% | 85.31 | 4.3% | $92.88m |
Company Profile
Enzo Biochem, Inc. engages in the development, manufacture and sale of technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians globally. It operates through the following segments: Enzo Clinical Laboratory Services, Enzo Life Sciences Products, and Enzo Therapeutics. The Enzo Clinical Laboratory Services segment includes clinical reference laboratory providing a wide range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. The Enzo Life Sciences Products segment manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. The Enzo Therapeutics segment develops multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.